These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 26064978)

  • 1. Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome.
    Thorp AA; Schlaich MP
    J Diabetes Res; 2015; 2015():341583. PubMed ID: 26064978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mediators of sympathetic activation in metabolic syndrome obesity.
    Straznicky NE; Eikelis N; Lambert EA; Esler MD
    Curr Hypertens Rep; 2008 Dec; 10(6):440-7. PubMed ID: 18959829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome.
    Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Karapanagiotidis S; Wong C; Richards K; Marusic P; Dixon JB; Schlaich MP; Lambert EA
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1701-7. PubMed ID: 24937541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance and sympathetic overactivity in women.
    Kaaja RJ; Pöyhönen-Alho MK
    J Hypertens; 2006 Jan; 24(1):131-41. PubMed ID: 16331111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perturbed autonomic nervous system function in metabolic syndrome.
    Tentolouris N; Argyrakopoulou G; Katsilambros N
    Neuromolecular Med; 2008; 10(3):169-78. PubMed ID: 18224460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.
    Lambert GW; Straznicky NE; Lambert EA; Dixon JB; Schlaich MP
    Pharmacol Ther; 2010 May; 126(2):159-72. PubMed ID: 20171982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroadrenergic dysfunction in obesity: an overview of the effects of weight loss.
    Straznicky NE; Lambert GW; Lambert EA
    Curr Opin Lipidol; 2010 Feb; 21(1):21-30. PubMed ID: 19809312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance and the sympathetic nervous system.
    Egan BM
    Curr Hypertens Rep; 2003 Jun; 5(3):247-54. PubMed ID: 12724058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sympathetic nervous system and the metabolic syndrome.
    Mancia G; Bousquet P; Elghozi JL; Esler M; Grassi G; Julius S; Reid J; Van Zwieten PA
    J Hypertens; 2007 May; 25(5):909-20. PubMed ID: 17414649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and adipokines: effects on sympathetic overactivity.
    Smith MM; Minson CT
    J Physiol; 2012 Apr; 590(8):1787-801. PubMed ID: 22351630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sympathetic system activity in obesity and metabolic syndrome.
    Tentolouris N; Liatis S; Katsilambros N
    Ann N Y Acad Sci; 2006 Nov; 1083():129-52. PubMed ID: 17148737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sympathetic nervous system alterations in human hypertension.
    Grassi G; Mark A; Esler M
    Circ Res; 2015 Mar; 116(6):976-90. PubMed ID: 25767284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome: a sympathetic disease?
    Schlaich M; Straznicky N; Lambert E; Lambert G
    Lancet Diabetes Endocrinol; 2015 Feb; 3(2):148-57. PubMed ID: 24731670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension.
    Modan M; Halkin H
    Diabetes Care; 1991 Jun; 14(6):470-87. PubMed ID: 1864220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome.
    Seravalle G; Grassi G
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):175-9. PubMed ID: 26942609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity and the sympathetic nervous system.
    Grassi G; Cattaneo BM; Seravalle G; Colombo M; Cavagnini F; Mancia G
    Blood Press Suppl; 1996; 1():43-6. PubMed ID: 9162437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of sympathetic nervous system activity associate with complex plasma lipids in metabolic syndrome subjects.
    Nestel PJ; Khan AA; Straznicky NE; Mellett NA; Jayawardana K; Mundra PA; Lambert GW; Meikle PJ
    Atherosclerosis; 2017 Jan; 256():21-28. PubMed ID: 27940403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in sympathetic activity in obesity and its related hypertension.
    Fu Q
    Ann N Y Acad Sci; 2019 Oct; 1454(1):31-41. PubMed ID: 31087350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation.
    Carnagarin R; Tan K; Adams L; Matthews VB; Kiuchi MG; Marisol Lugo Gavidia L; Lambert GW; Lambert EA; Herat LY; Schlaich MP
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance.
    Lambert EA; Teede H; Sari CI; Jona E; Shorakae S; Woodington K; Hemmes R; Eikelis N; Straznicky NE; De Courten B; Dixon JB; Schlaich MP; Lambert GW
    Clin Endocrinol (Oxf); 2015 Dec; 83(6):812-9. PubMed ID: 25926334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.